Supplementary Tables 1-3 from Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Autor: Neil J. Clendeninn, Prabhu Rajagopalan, Michael Jeffers, Ronald L. Dubowy, Li-Tain Yeh, Zancong Shen, Jeffrey N. Miner, Cory Iverson, Beth Sheedy, Wen W. Ma, Grace K. Dy, Ramesh K. Ramanathan, Glen J. Weiss, Karl D. Lewis, Lia Gore, S. Gail Eckhardt, Diane P. Leffingwell, Alex A. Adjei, Daniel D. Von Hoff, Colin D. Weekes
Rok vydání: 2023
DOI: 10.1158/1078-0432.22449329.v1
Popis: Table S1: Dose-limiting toxicities; Table S2:Multiple-dose pharmacokinetic parameters (geometric mean (%CV) of BAY 86-9766 and metabolite M17 on Course 1, Day 22 (representing exposure after 15 days of continuous dosing) for once-daily dosing cohorts; Table S3: Multiple-dose pharmacokinetic parameters of BAY 86-9766 and metabolite M17 on Course 1, Day 22 (representing exposure after 15 days of continuous dosing) for twice-daily dosing cohorts
Databáze: OpenAIRE